Wedbush Starts Synageva BioPharma (GEVA) at Outperform; Focused on Rare Diseases With Its Golden Eggs
Tweet
Share
E-mailGet Alerts GEVA Hot Sheet
Price: $238.60 --0%
Rating Summary:
6 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
6 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Wedbush initiates coverage on Synageva BioPharma (NASDAQ: GEVA) with a Outperform. PT $32.00.
Wedbush analyst says, "We view upcoming Phase I/II data releases in 2012 as likely to build on already-positive results reported in one infant with Wolman Disease. We believe that, as with other enzyme replacement therapies (ERTs) for ultra-rare diseases, early signals of efficacy may be more predictive of eventual clinical success and approval than such signals in other disease areas."
"We view GEVA’s clinically validated EW expression system as both a source of new, previously inaccessible ERTs and potentially valuable licensing agreements for areas outside of Synageva’s focus."
For an analyst ratings summary and ratings history on Synageva BioPharma click here. For more ratings news on Synageva BioPharma click here.
Shares of Synageva BioPharma closed at $19.82 yesterday.
Wedbush analyst says, "We view upcoming Phase I/II data releases in 2012 as likely to build on already-positive results reported in one infant with Wolman Disease. We believe that, as with other enzyme replacement therapies (ERTs) for ultra-rare diseases, early signals of efficacy may be more predictive of eventual clinical success and approval than such signals in other disease areas."
"We view GEVA’s clinically validated EW expression system as both a source of new, previously inaccessible ERTs and potentially valuable licensing agreements for areas outside of Synageva’s focus."
For an analyst ratings summary and ratings history on Synageva BioPharma click here. For more ratings news on Synageva BioPharma click here.
Shares of Synageva BioPharma closed at $19.82 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- Raymond James Starts SpyGlass Pharma (SGP) at Outperform
- UBS Starts Schrodinger (SDGR) at Neutral
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
